Practical insights into bispecific antibody therapy in multiple myeloma DOI Creative Commons
Yumena Kawasaki,

Sara Winger,

Naseem Esteghamat

et al.

Expert Review of Anticancer Therapy, Journal Year: 2024, Volume and Issue: unknown

Published: Dec. 27, 2024

Introduction The rise of recent novel therapies teclistamab, elranatamab, and talquetamab for the treatment relapsed/refractory multiple myeloma (RRMM) is a rapidly evolving area with significant clinical implications that require exploration evaluation.

Language: Английский

SOHO State of the Art Updates and Next Questions | Novel Immunotherapy Combinations for the Treatment of Indolent B-Cell Lymphoma DOI
Tony Zhuang, Chen Zhang,

Paolo Strati

et al.

Clinical Lymphoma Myeloma & Leukemia, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 1, 2025

Language: Английский

Citations

0
An evaluation of odronextamab for the treatment of multiple subtypes of relapsed/refractory B-cell non-hodgkin lymphoma DOI

Elena Bayly-McCredie,

H. Miles Prince, Costas K. Yannakou

et al.

Expert Opinion on Biological Therapy, Journal Year: 2025, Volume and Issue: unknown

Published: March 19, 2025

Patients with relapsed/refractory B-cell non-Hodgkin lymphoma (B-NHL) have a poor median survival rate when treated traditional salvage therapies. Bispecific antibodies (BsAbs) are an emerging class of 'off-the-shelf' immunotherapies that show promising efficacy in this population. Odronextamab is CD20×CD3 targeting bispecific antibody being investigated multiple subtypes B-NHL. This article describes the development odronextamab from pre-clinical work through to ongoing clinical trials The structure, safety, and administration discussed. Studies were selected for inclusion by performing search PubMed, EMBASE, Cochrane Library relevant conference abstracts 2014 2024. clinicaltrials.gov website reference lists included studies also reviewed. has demonstrated manageable safety low rates immune effector cell-associated neurotoxicity syndrome ;(ICANS) high response rare aggressive B-NHL particularly noteworthy. High severe infections remain challenge BsAbs, further prophylactic efforts required reduce risk. Clinical combination therapies improve utility BsAb across wider range settings

Language: Английский

Citations

0
Measurable Residual Disease Testing During Treatment with Bispecific Antibodies for Lymphoma DOI Open Access
Gaston Jean-Louis, Hua‐Jay J. Cherng

Cancers, Journal Year: 2025, Volume and Issue: 17(7), P. 1153 - 1153

Published: March 29, 2025

The introduction of bispecific antibodies (BsAbs) has led to significant improvements in survival for patients with relapsed and refractory B-cell lymphomas. Despite these advances, there remains a number who experience disease progression after novel therapies. Predicting which may respond certain treatments the durability their responses challenging. Measurable residual (MRD) become easier detect quantify through use genomic next-generation sequencing tools been studied as possible biomarker predict long-term outcomes risk-stratify BsAb therapy several lymphoma subtypes. Here, we review recent data demonstrating that MRD negativity is associated radiographic response improved progression-free survival. Because heterogeneity assay choice, assessment timing, technical parameters, further work needed before testing ready be incorporated into clinical practice context treatment

Language: Английский

Citations

0
Easy as ABC: Managing Toxicities of Antibody-Drug Conjugates, Bispecific Antibodies, and CAR T-Cell Therapies DOI
Michael D. Jain, Jeremy S. Abramson, Stephen M. Ansell

et al.

American Society of Clinical Oncology Educational Book, Journal Year: 2025, Volume and Issue: 45(3)

Published: April 28, 2025

Antibody-drug conjugates (ADCs), bispecific antibodies that engage T cells (BsAbs), and chimeric antigen receptor (CAR) are widely used standard-of-care therapies have revolutionized the treatment of lymphoid plasma cell malignancies. With recent regulatory approvals, these poised to also revolutionize common solid tumors become a part everyday lexicon, ABCs, practicing oncologist. Drawing from experience in hematology, we review early, late, rare toxicities ADCs, BsAbs, CAR provide general principles for their management.

Language: Английский

Citations

0
Nebenwirkungsmanagement bei neuen Substanzklassen in der Hämatologie DOI

Juliane Brandt

Im Focus Onkologie, Journal Year: 2024, Volume and Issue: 27(5), P. 34 - 37

Published: Oct. 1, 2024

Citations

0
Trispecific anti-CD3/BCMA/CD38 antibodies for multiple myeloma: a patent evaluation of US20240132615 DOI
Cindy Bandala,

Donaciano Flores-Robles,

Pavel Sierra-Martínez

et al.

Expert Opinion on Therapeutic Patents, Journal Year: 2024, Volume and Issue: unknown

Published: Oct. 26, 2024

CD38 and BCMA are proteins expressed at high levels in multiple myeloma cells, so they targets for the development of mono- or multispecific antibodies.

Language: Английский

Citations

0
Practical insights into bispecific antibody therapy in multiple myeloma DOI Creative Commons
Yumena Kawasaki,

Sara Winger,

Naseem Esteghamat

et al.

Expert Review of Anticancer Therapy, Journal Year: 2024, Volume and Issue: unknown

Published: Dec. 27, 2024

Introduction The rise of recent novel therapies teclistamab, elranatamab, and talquetamab for the treatment relapsed/refractory multiple myeloma (RRMM) is a rapidly evolving area with significant clinical implications that require exploration evaluation.

Language: Английский

Citations

0